Revolution Medicines, Inc. (RVMD)
186.99
-0.70
(-0.37%)
USD |
NASDAQ |
Oct 23, 16:00
184.37
-2.62
(-1.40%)
After-Hours: 20:00
Revolution Medicines Enterprise Value : 37.31B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 37.31B |
| October 22, 2026 | 37.46B |
| October 21, 2026 | 38.88B |
| October 20, 2026 | 39.36B |
| October 19, 2026 | 36.28B |
| October 16, 2026 | 35.38B |
| October 15, 2026 | 37.80B |
| October 14, 2026 | 38.71B |
| October 13, 2026 | 37.62B |
| October 12, 2026 | 38.80B |
| October 09, 2026 | 37.91B |
| October 08, 2026 | 37.56B |
| October 07, 2026 | 40.29B |
| October 06, 2026 | 40.07B |
| October 05, 2026 | 41.75B |
| October 02, 2026 | 41.52B |
| October 01, 2026 | 41.36B |
| September 30, 2026 | 41.23B |
| September 29, 2026 | 41.06B |
| September 28, 2026 | 40.47B |
| September 25, 2026 | 41.17B |
| September 24, 2026 | 40.07B |
| September 23, 2026 | 38.12B |
| September 22, 2026 | 38.57B |
| September 21, 2026 | 38.55B |
| Date | Value |
|---|---|
| September 18, 2026 | 38.16B |
| September 17, 2026 | 39.45B |
| September 16, 2026 | 39.23B |
| September 15, 2026 | 41.14B |
| September 14, 2026 | 41.20B |
| September 11, 2026 | 40.91B |
| September 10, 2026 | 40.82B |
| September 09, 2026 | 41.75B |
| September 08, 2026 | 41.67B |
| September 04, 2026 | 42.25B |
| September 03, 2026 | 42.43B |
| September 02, 2026 | 42.08B |
| September 01, 2026 | 42.22B |
| August 31, 2026 | 41.29B |
| August 28, 2026 | 41.79B |
| August 27, 2026 | 44.63B |
| August 26, 2026 | 43.41B |
| August 25, 2026 | 42.54B |
| August 24, 2026 | 42.58B |
| August 21, 2026 | 42.13B |
| August 20, 2026 | 42.62B |
| August 19, 2026 | 43.24B |
| August 18, 2026 | 43.53B |
| August 17, 2026 | 42.67B |
| August 14, 2026 | 40.90B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Moderna, Inc. | 75.99B |
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Intellia Therapeutics, Inc. | 1.205B |
| Oncolytics Biotech, Inc. | 58.94M |
| Twist Bioscience Corp. | 8.696B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -644.37M |
| Total Expenses (Quarterly) | 644.37M |
| EPS Diluted (Quarterly) | -3.055 |
| Earnings Yield | -4.71% |
| Normalized Earnings Yield | -4.391 |